Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from MRK

EMA's Advisory Group Backs Approval For Merck's Keytruda In Various Cancer Settings

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Merck & Co Inc (NYSE: MRK) for

Benzinga

Merck Continues to See Executive Exodus; Here's A Look At All Recent Departures

Executive churn at pharma giant Merck & Co., Inc. (NYSE: MRK) has increased in recent times, so much so that it has caused stakeholders to sit up and take notice.

Benzinga

Merck Lays Out Keytruda Data In Post Surgery Early-Stage Lung Cancer Setting

Merck & Co Inc (NYSE: MRK) announced results from the Phase 3 KEYNOTE-091 trial evaluating Keytruda compared to placebo for adjuvant treatment of non-small cell lung cancer (NSCLC).

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Analyzing Merck & Company Inc. New's Short Interest

Merck & Company Inc (new's (NYSE: MRK) short percent of float has fallen 12.5% since its last report. The company recently reported that it has 17.65 million shares sold short, which is 0.7% of all regular shares that are available for trading.

Benzinga

Merck-AstraZeneca Stop Keytruda/Lynparza Combo Trial In Prostate Cancer Patients

Merck & Co Inc (NYSE: MRK) will stop the Phase 3 KEYLYNK-010 trial investigating Keytruda combined with Lynparza for metastatic castration-resistant prostate cancer (mCRPC).

Benzinga

Why Alpine Immune's Shares Are Falling Today

The FDA has placed a partial clinical hold on Alpine Immune Sciences Inc's (NASDAQ:ALPN) NEON-2 trial evaluating davoceticept (ALPN-202) in combination with pembrolizumab in adults with advanced malignancies. The partial clinical hold was prompted by Alpine's report of patient death in the NEON-2 trial. The participant had choroidal melanoma previously treated with nivolumab and…

Benzinga

Merck's Keytruda Shows Improved Metastasis-Free Survival In Melanoma Patients

Merck & Co Inc (NYSE: MRK) announced data from Phase 3 KEYNOTE-716 trial of Keytruda (pembrolizumab) as adjuvant treatment for patients with resected stage IIB and IIC melanoma.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

WHO Conditionally Recommends Merck's COVID-19 Antiviral Pill For High-Risk Patients

A World Health Organization (WHO) panel has backed the use of Merck & Co Inc's (NYSE:MRK) COVID-19 antiviral pill for high-risk patients. The expert panel conditionally recommended molnupiravir for patients with non-severe disease at high risk of hospitalization, such as the immunocompromised, the unvaccinated, older people, and those with chronic conditions. The recommendation was…

Benzinga

Looking Into Merck & Company Inc (new's Recent Short Interest)

Merck & Company Inc (new's (NYSE: MRK) short percent of float has fallen 13.98% since its last report. The company recently reported that it has 20.09 million shares sold short, which is 0.8% of all regular shares that are available for trading.

Benzinga

5 Defensive Stocks to Own for Consistent Dividends and Stable Earnings

Concerns over the Russia-Ukraine war and high inflation have significantly affected the global equity markets lately. As the stock market is expected to remain highly volatile in the coming weeks, it could be wise to bet on defensive stocks Walmart (WMT), Novartis (NVS), Merck & Co. (MRK), GlaxoSmithKline (GSK), and…

StockNews.com

3 Wide-Moat Stocks to Withstand a Market Downturn: Microsoft, Merck, and Blackbaud

The major stock market indices suffered a sell-off as the news of Russia’s military action in Ukraine broke. But because wide-moat companies generally fare well in challenging times like these, we believe VanEck Vectors Morningstar Wide Moat ETF’s (MOAT) holdings Microsoft (MSFT), Merck & Co. (MRK), and Blackbaud (BLKB) might…

StockNews.com

This Is What Whales Are Betting On Merck & Co

Someone with a lot of money to spend has taken a bearish stance on Merck & Co (NYSE:MRK). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Merck & Co Whale Trades Spotted

Benzinga

Stabilize Your Portfolio with These 5 High-Quality Stocks

The stock indices are down, heading for a second straight losing week on investor concerns about geopolitical tensions and the Fed’s actions. And the market is expected to remain volatile in the near term. Hence, we think high-quality stocks Merck & Co. (MRK), Archer-Daniels-Midland (ADM), Baxter (BAX), McKesson (MCK), and…

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

See Why Did FDA Update Merck's COVID-19 Pill Emergency Use Authorization

The FDA has revised the Emergency Use Authorization (EUA) for Merck & Co Inc's (NYSE: MRK) COVID-19 pill mo

Benzinga

South Africa Authorizes Merck's COVID-19 Antiviral Pill, But Government Not Buying: Reuters

South Africa's government said it was not planning to buy Merck & Co Inc's (NYSE: MRK) COVID-19 treatment pill molnupiravir for cost reasons, despite the drug gaining approval in the country.

Benzinga

Merck Inks Oncology, Neurology Drug Discovery Pact With British Biotech, Curve Therapeutics

Privately-held Curve Therapeutics has inked a contract with Merck & Co Inc (NYSE: MRK) to discover and validate modulators of up to five therapeutic targets using its Microcycle technology, initially for oncology and neurology indications.

Benzinga

Merck & Co Whale Trades For February 10

Someone with a lot of money to spend has taken a bullish stance on Merck & Co (NYSE:MRK). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Merck Clocked $950M Sales In Q4 From COVID-19 Treatment, Issues FY22 Sales

Merck & Co Inc's (NYSE: MRK) Q4 sales re

Benzinga

Recap: Merck & Co Q4 Earnings

Merck & Co (NYSE:MRK) reported its Q4 earnings results on Thursday, February 3, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Benzinga

Preview: Merck & Co's Earnings

Merck & Co (NYSE:MRK) is set to give its latest quarterly earnings report on Thursday, 2022-02-03. Here's what investors need to know before the announcement. Analysts estimate that Merck & Co will likely report an Earnings Per Share (EPS) of $1.53.

Benzinga

Analyst Ratings For Merck & Co

Analysts have provided the following ratings for Merck & Co (NYSE:MRK) within the last quarter:

Benzinga

Merck's COVID-19 Pill works Against Omicron, Lab Studies Show

Merck & Co Inc (NYSE: MRK) and its partner Ridgeback Biotherapeutics said six lab studies showed their investigational oral COVID-19 drug molnupiravir was

StockNews.com

3 Top Dow Jones Stocks to Safeguard Your Portfolio

The market remains turbulent amid worries related to rising inflation, looming interest rate hikes, and geopolitical tensions. However, the Dow Jones Industrial Average is down the least out of the three major indices. Investing in hot Dow stock Merck (MRK), Amgen (AMGN), and Walgreens (WBA) could help safeguard your portfolio…

Benzinga

Britain To Test Merck - Ridgeback Biotherapeutics' COVID-19 Antiviral Pill In Hospitalized Patients

British scientists will start testing Merck & Co Inc (NYSE: MRK) and Ridgeback Biotherapeutics' COVID-19 antiviral pill molnupiravir as a possible treatment for patients hospitalized with COVID-19,

1 … 5 6 7 8

Organisations

World Health Organization

European Medicines Agency

77 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Places

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.